These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 26099676)

  • 1. (18)F-Flourodeoxy-Glucose PET/Computed Tomography in Brain Tumors: Value to Patient Management and Survival Outcomes.
    Wray R; Solnes L; Mena E; Meoded A; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):423-30. PubMed ID: 26099676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET with Fluorodeoxyglucose F 18/Computed Tomography in the Clinical Management and Patient Outcomes of Esophageal Cancer.
    Kwee RM; Marcus C; Sheikhbahaei S; Subramaniam RM
    PET Clin; 2015 Apr; 10(2):197-205. PubMed ID: 25829086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI.
    Santra A; Kumar R; Sharma P; Bal C; Kumar A; Julka PK; Malhotra A
    Eur J Radiol; 2012 Mar; 81(3):508-13. PubMed ID: 21353420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PET/computed tomography and lymphoma.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2013 Sep; 51(5):833-44. PubMed ID: 24010908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
    Li DL; Xu YK; Wang QS; Wu HB; Li HS
    Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
    Allen-Auerbach M; de Vos S; Czernin J
    Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/Computed Tomography and Patient Outcomes in Melanoma.
    Rohren EM
    PET Clin; 2015 Apr; 10(2):243-54. PubMed ID: 25829089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of F-18 FDG and C-11 methionine PET/CT for the evaluation of recurrent primary brain tumors.
    Tripathi M; Sharma R; Varshney R; Jaimini A; Jain J; Souza MM; Bal J; Pandey S; Kumar N; Mishra AK; Mondal A
    Clin Nucl Med; 2012 Feb; 37(2):158-63. PubMed ID: 22228339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fludeoxyglucose F 18 PET-Computed Tomography: Management Changes Effecting Patient Outcomes in Gynecologic Malignancies.
    Brunetti JC
    PET Clin; 2015 Jul; 10(3):395-409. PubMed ID: 26099674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
    Tirumani SH; LaCasce AS; Jacene HA
    PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiation between malignant transformation and tumour recurrence by (68)Ga-bombesin and (18)F-FDG-PET, in patients with low grade gliomas.
    Seiz M; Dimitrakopoulou-Strauss A; Schubert GA; Weinmann C; Strauss LG; Eisenhut M; Tuettenberg J
    Hell J Nucl Med; 2008; 11(3):149-52. PubMed ID: 19081856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of brain FDG-PET in primary CNS lymphoma.
    Mohile NA; Deangelis LM; Abrey LE
    Clin Adv Hematol Oncol; 2008 Nov; 6(11):818-20, 840. PubMed ID: 19194366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET/CT: appropriate application in lymphoma.
    Wang X
    Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ¹⁸F-fluorodeoxyglucose PET/computed tomography for primary brain tumors.
    Segtnan EA; Hess S; Grupe P; Høilund-Carlsen PF
    PET Clin; 2015 Jan; 10(1):59-73. PubMed ID: 25455880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of FDG PET/CT in Patient Management and Outcome of Skeletal and Soft Tissue Sarcomas.
    Sheikhbahaei S; Marcus C; Hafezi-Nejad N; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):375-93. PubMed ID: 26099673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET/CT in Pancreatic and Hepatobiliary Carcinomas: Value to Patient Management and Patient Outcomes.
    Parikh U; Marcus C; Sarangi R; Taghipour M; Subramaniam RM
    PET Clin; 2015 Jul; 10(3):327-43. PubMed ID: 26099670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.